RedHill Biopharma (RDHL) Cash from Financing Activities (2012 - 2022)

RedHill Biopharma (RDHL) has 11 years of Cash from Financing Activities data on file, last reported at $7.2 million in Q4 2022.

• On a quarterly basis, Cash from Financing Activities fell 59.02% year-over-year to $7.2 million in Q4 2022; TTM through Dec 2022 was $11.5 million, a 84.41% decrease from a year earlier, with the FY2025 full-year figure at $7.3 million, down 13.07% from the prior year.
• Cash from Financing Activities for Q4 2022 stood at $7.2 million, up from -$5.7 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for RDHL reached as high as $59.1 million in Q1 2020 and fell as low as -$5.7 million in Q3 2022.
• Historically, Cash from Financing Activities has averaged $13.0 million across 5 years, with a median of $7.2 million in 2022.
• Across the five-year window, Cash from Financing Activities soared 78406.67% in 2018 and sank 472.67% in 2022, its largest moves.
• Year by year, Cash from Financing Activities stood at $18.4 million in 2018, then jumped by 96.67% to $36.1 million in 2019, then tumbled by 78.0% to $7.9 million in 2020, then jumped by 121.25% to $17.6 million in 2021, then slumped by 59.02% to $7.2 million in 2022.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $7.2 million in Q4 2022, -$5.7 million in Q3 2022, and $14.9 million in Q2 2022.